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Regulatory T cells (Tregs) are important for the induction and maintenance of
peripheral tolerance therefore, they are key in preventing excessive immune responses
and autoimmunity. In the last decades, several reports have been focussed on
understanding the biology of Tregs and their mechanisms of action. Preclinical studies
have demonstrated the ability of Tregs to delay/prevent graft rejection and to control
autoimmune responses following adoptive transfer in vivo. Due to these promising
results, Tregs have been extensively studied as a potential new tool for the prevention
of graft rejection and/or the treatment of autoimmune diseases. Currently, solid organ
transplantation remains the treatment of choice for end-stage organ failure. However,
chronic rejection and the ensuing side effects of immunosuppressants represent the
main limiting factors for organ acceptance and patient survival. Autoimmune disorders
are chronic diseases caused by the breakdown of tolerance against self-antigens.
This is triggered either by a numerical or functional Treg defect, or by the resistance
of effector T cells to suppression. In this scenario, patients receiving high doses of
immunosuppressant are left susceptible to life-threatening opportunistic infections and
have increased risk of malignancies. In the last 10 years, a few phase I clinical trials aiming
to investigate safety and feasibility of Treg-based therapy have been completed and
published, whilst an increasing numbers of trials are still ongoing. The first results showed
safety and feasibility of Treg therapy and phase II clinical trials are already enrolling. In this
review, we describe our understanding of Tregs focussing primarily on their ontogenesis,
mechanisms of action and methods used in the clinic for isolation and expansion.
Furthermore, we will describe the ongoing studies and the results from the first clinical
trials with Tregs in the setting of solid organ transplantation and autoimmune disorders.
Finally, we will discuss strategies to further improve the success of Treg therapy.
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INTRODUCTION
Since the discovery in 1969 of the suppressor T cells (1),
the regulatory T cells (Tregs) research field has undergone an
incredible boom over the years. Studies on the biology of Tregs
have attracted a lot of attention and our knowledge about
their development and differentiation has increased enormously.
The breakthrough in this field dates back to the discovery, in
1995, of a subset of thymus derived CD4+ T cells expressing
high levels of IL-2Rα (CD25) able to protect thymectomized
mice from autoimmunity (2). Since then, well-cited papers
have shown the crucial role of Tregs in maintaining immune
homeostasis (3) and preventing autoimmunity (4). Despite
the improvement in Treg biology, nowadays there are no
specific markers to characterize human Tregs. Differently from
the mouse counterpart, the sole expression of CD25 and the
transcriptional regulator forkhead box P3 (FOXP3) (5) is not
sufficient for characterizing human Tregs, since effector T cells
can upregulate these markers after activation. However, the
methylation status of the Treg-specific demethylated region
(TSDR) (6), a conserved non-coding element within the FoxP3
gene locus, can be used for the identification of the “real” human
Tregs (7). The analysis of TSDR methylation does not represent
a suitable tool for their isolation; currently the expression of
CD4, CD25, and lack of the α-chain of IL-7R (CD127) (8)
are used for Tregs purification. In preclinical studies, human
CD4+CD25+CD127− Tregs have been shown to be effective in
preventing Graft vs. Host Disease (GvHD) (9, 10), autoimmune
diseases (11, 12) and delaying graft rejection (13, 14). The
positive outcomes gave the rationale to apply Tregs for the
treatment of human diseases and results from the first clinical
trials with adoptively transferred Tregs were published in 2009
(15).
Solid organ transplantation represents the only treatment for
end-stage organ diseases. Over the years, several strategies
have been applied in order to improve transplantation
outcomes and short-term graft survival (16). A better
selection of donors and recipients associated with improved
immunosuppressive schemes and patients’ management has
been crucial for ameliorating the graft survival in early stages.
Long-term organ acceptance is a different story, remaining
constant over the past decades (17). The immunosuppressive
regimen, consisting of a combination of different drugs,
aims to dampen the response of the immune system to
the graft. Although successful in controlling the immune
response early post-transplant, it is linked with detrimental
side effects. Cardiovascular diseases, cancer, kidney failure
and infections represent the main side effects that can
cause graft loss and death (18). Long-term outcomes and
finally operational tolerance are key for a successful organ
transplantation. Different strategies are under investigation
with the aim to reduce the use of immunosuppressive drugs.
In this scenario, Tregs might represent a valid solution for
controlling the immune response and inducing transplantation
tolerance.
Autoimmune disorders are chronic diseases caused by the
breakdown of tolerance against self-antigens. Usually they
involve a specific region of the body such as the joints in
rheumatoid arthritis (RA) or the pancreatic cells in type 1
diabetes mellitus (T1D). In other autoimmune diseases such as
systemic lupus erythematosus (SLE) multiple areas are affected.
The origin of autoimmune diseases is still a matter of debate;
one hypothesis involves a failure in central and peripheral
tolerance with the latter being associated with reduced Treg
number or failure in their function (19). Furthermore, the
combination of genetic and environmental risk factors has
been implicated in the ontogenesis of autoimmunity as well
(20). Similar to transplantation, immunosuppressive regimens
aim to inhibit the activation of the immune system and
reduce chronic inflammation. Different monoclonal antibodies
targeting co-stimulatory molecules (21), cytokines (22), and
lineage specific molecules (23) have been tested however, they
all aim to target the immune and autoimmune responses leaving
patients immunocompromised. For this reason, Tregs have been
suggested as an effective tool for the treatment of autoimmune
diseases.
TREGS ONTOGENESIS
The summation of the research over the past years has
demonstrated that the thymus is the crucial organ for the
generation of Tregs (24). Animal models have shown that the
differentiation of thymus-derived Tregs (tTregs) depends on
T cell receptor (TCR) signaling, particularly the strength and
duration of the signal (25). Despite technical limitations, this has
been confirmed in humans as well (24). In thymus, immature
CD4 single positive (SP) cells receive a TCR signal of varied
strength, which will drive their fate. Following a TCR signal of
high strength, most CD4 SP cells undergo negative selection,
whereas those receiving TCR signals of intermediate strength are
able to escape deletion and are committed to differentiate into
Tregs (26). Nevertheless, whether there are differences between
TCR signals for conventional T cells (Tconv) and Tregs is still an
open question. Some pieces of evidence so far support the idea
of “quantitative” difference in signaling, but it is also plausible
that TCR signals might be “qualitatively” different. Beyond TCR
signaling, CD28 is also crucial in the generation of tTregs. In
fact, both CD28–deficient and CD80-CD86-deficient mice have
decreased number of Tregs (27). Several other factors, including
NFAT/AP1, ICOS/ICOSL and thymic stromal lymphopoietin
(TSLP) are involved in the transcriptional control of human Treg
differentiation (28–30). FOXP3 expression requires the presence
of γ chain cytokines (IL-2, IL-15, and IL-7) and the reduction
of PI3K-mTOR signaling pathway. Mice deficient in IL-2 or
IL-2Rα have decreased number of FoxP3+ thymocytes, while
ablation of IL-15 and IL-7 alone does not have such effect (5).
The essential role of IL-2 in the generation of Tregs has been
confirmed in humans as well (29). Phosphatidylinositol 3-kinase
(PI3K) is induced by TCR and CD28 signaling and through
the activation of Akt-mTOR pathway, antagonizes FOXP3
expression, thereby inhibiting the development and suppressive
function of tTregs (31). Conversely, the hyper-activation of
this pathway in Tconv cells has been suggested as a possible
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mechanism to overcome Treg suppression (32). In recent years,
it has been demonstrated that the demethylation status of a
TSDR is essential for human Treg lineage maintenance (6).
Therefore, both FOXP3 expression and TSDR demethylation are
essential for tTreg lineage commitment. Together, these findings
demonstrate that TCR signaling in combination with other cell-
intrinsic and extrinsic signals orchestrates human tTreg cell
differentiation.
In addition to tTreg, naïve FOXP3−CD4+ T cells can
differentiate in the periphery to become FOXP3+cells, which are
known as induced Tregs (iTregs) or peripheral Tregs (pTregs).
Differently from tTregs, the generation of iTregs is likely
promoted by non-self-antigens (allergens, food, microbiota) (33).
It has been also shown that a distinct TCR repertoire and ligand
specificity support the generation of iTregs. These TCRs are
of high affinity and their sequences only partially overlap with
the TCRs used by tTregs. Additionally, an efficient induction
of FOXP3 and iTreg generation occurs in vivo upon TCR
stimulation together with suboptimal co-stimulation (decreased
CD28 signaling) (34). Therefore, TCRs that recognize antigens
to which an organism is chronically exposed promote the
generation of iTregs. Low levels of costimulatory molecules
in the presence of anti-inflammatory molecules secreted by
tolerogenic DC cells (tDCs) promote the differentiation of iTreg
cells as well (35). Beyond TCR signaling and suboptimal co-
stimulation, the polarization of naïve CD4+ T cells into iTregs
requires the combination of TGF-β and IL-2 (36). For example,
several animal studies have shown that TGF-β/TCR-mediated
iTreg cell generation is strictly dependent on IL-2 signaling. IL-
2 promotes the activation of Foxp3 locus through STAT5 and
constrains the differentiation of activated CD4+ T cells into Th17
cells (37, 38). So far, in vitro TGF-β-induced iTreg cells have
been considered a valid approach to study the development of
iTreg cells in vivo. However, this experimental method fails in
recapitulating the epigenetic and transcriptional characteristics
of in vivo induced iTreg cells, namely transient suppressive
ability and unstable FOXP3 expression, precluding therefore
their use in the clinic (39). Inducible T regulatory type 1
(Tr1) cells are a subset of iTregs characterized by the ability
to produce the immunosuppressive cytokine IL-10 (40). Tr1
can only transiently up-regulate FoxP3 following stimulation.
These cells have been shown to maintain peripheral tolerance,
modulate effector T cell responses in several autoimmune
diseases and prevent allograft rejection (40). The possibility of
generating in vitro expanded Ag-specific Tr1 cells has encouraged
their clinical use in autoimmunity and Graft vs. Host Disease
(GvHD).
Current evidence indicates that tTregs and iTregs are
designated to play different roles in different tissues. Owing to
the nature of iTreg differentiation induced by non-self- antigens
and a particular TCR signaling combined with other signals, such
as TGF-β and IL-2, these cells are assumed to be more functional
for maintaining mucosal tolerance. iTregs may therefore control
immune responses to commensal antigens and prevent allergic-
type reactions.
“HETEROGENEITY OF TREGS”
Tregs in circulation are considered heterogeneous, this is mainly
due to their plasticity and the capacity to acquire features
specific to the type of immune response they control. In the
literature, Tregs are divided in subpopulations according to
the sites of differentiation and the expression of well-known
functional markers. However, this does not allow a full
distinction due to the overlap and redundancy between many
of these parameters. For the first time in 2009, Miyara et al.
demonstrated that human Tregs consists of three subpopulations
based on their expression levels of FOXP3 and CD45RA (41).
Tregs were classified as naive/resting (CD45RA+FoxP3low),
effectors (CD45RA−FoxP3high), and cytokine-producing
(CD45RA−FoxP3low). Naive Tregs are considered the “real
Tregs” arising from thymus with a fully demethylated FoxP3
locus. Effectors Tregs are the active population in vivo while the
cytokine-producing Tregs include those cells able to produce
pro-inflammatory cytokines like IL-17 and IFN-γ but still able to
suppress. More recently, human Tregs named T helper-(Th-) like
Tregs have been described (42). These memory Tregs mirror the
classical CD4+ Th population expressing the same chemokine
receptors CXCR3, CCR6 and CCR4, typically expressed by
T-bet+-Th1, RORgt+-Th17, and GATA3+-Th2, respectively.
We have fully characterized these subsets showing their cytokine
production, suppressive and migratory ability (43). In vitro, all
Th-like Tregs are functional with no preferential suppressive
ability toward the cognate Th counterpart. This highlights the
importance of Th/Tregs co-localization for the control of the
immune system activation. The ontogenesis of these subsets
is still under debate due to the high Treg plasticity, which can
be detrimental in the setting of autoimmune diseases (44). In
this scenario, Tregs acquire Th phenotypes associated with a
reduced function despite maintaining Foxp3 expression and
demethylation. The frequency of Th1-like Tregs is increased in
patients with T1D (45), multiple sclerosis (46) and autoimmune
hepatitis (47) and it is associated with a reduced suppressive
ability. Similarly, Th2-like Tregs are increased in the skin but
not in the peripheral blood of patients with systemic sclerosis
(48). Whereas, Th17-like Tregs are increased in psoriasis (49)
patients and inflammatory bowel diseases (50, 51) with no
loss of function. However, the origin and the fate of Th17-like
Tregs is matter of debate as some authors suggested that they
might represent a transient stage in the differentiation of Tregs
into Th17 cells (52). Under inflammatory conditions and
autoimmune diseases, FOXP3+ Tregs can convert into Th17
thus impairing immune homeostasis and contributing to the
progression and pathogenesis of the disease (44). As already
mentioned, the demethylation of the TSDR region is the key
determinant for Treg stability and function. FOXP3 is known
to neutralize RORγt transcription, the master transcription
factor of IL-17 producing Th17 cells (53). Therefore, a
highly stable Foxp3 expression in vitro is associated with a
small risk for IL-17 production in vivo under inflammatory
conditions.
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MECHANISMS BY WHICH TREGS
SUPPRESS
The mechanisms used by Tregs to suppress different immune
cells can either be considered direct whereby Tregs themselves
elicit a direct response on a target cell, or indirect, in which a
third-party cell or molecule is affected and in turn suppresses
the target cell (54). Examples of direct mechanisms include
the secretion of cytokines such as IL-10, TGFβ and IL-35 and
the production of granzyme and perforin, enzymes leading to
apoptosis in target cells (54). Indirect mechanisms include the
expression of CD39/CD73, which deplete the microenvironment
of extracellular ATP via the generation of adenosine and AMP,
molecules with immunosuppressive effects (54). Alternatively,
Tregs can influence changes in the microenvironment due to
their high expression of CD25. The high expression of this
receptor enables Tregs to uptake more IL-2 and “starve” the
surrounding cells of this cytokine (55). When considering
whether there is a “dominant” mechanism of suppression utilized
by Tregs, it is important to understand that different mechanisms
are utilized preferentially for the vast variety of target cells
and microenvironments in which Tregs act. Below, we explore,
more specifically the methods used on several “key” cell types
from both the innate and adaptive arms of the immune system
(Figure 1).
T-Lymphocytes
This includes of CD4+ andCD8+ cells. Tregs suppress CD4T cell
activation and proliferation by contact-dependent and contact-
independent mechanisms [extensively reviewed in (56)]. An
important factor for Treg suppressive ability on other T cells is
their localization. This is in line with the mutual distribution of
the Th-like Tregs and classical Th cells observed by us in human
thymus, spleen, liver, and colon (43). Additionally, Tregs can also
influence proliferation, activation and apoptosis of CD8+ T cells
(57, 58). As a result, the induction of high affinity effector and
memory CD8+ T cells is reduced.
B-Lymphocytes
B-Lymphocytes are important components of the adaptive
immune system acting largely by the production of antibodies;
however, they can act as APCs as well. B-cells require activation
by T-cells following antigen recognition. Upon activation, B-
cells differentiate into “effector” plasma cells which can produce
antibodies. Tregs have the potential to suppress autoreactive B-
cells in an antigen-specific manner and prevent the production
of harmful autoantibodies. This suppression requires PD-1
expression on autoreactive B cells and expression of the two PD-1
ligands (PDL-1 and 2) on Treg (Figure 1) (59). In addition, Tregs
are able to kill B-cell by releasing granzyme B and perforin (60).
Dendritic Cells
Dendritic cells (DCs) play a critical role in the regulation of the
adaptive immune response by activating resting naïve T cells. In
the setting of transplantation, they are key in mediating graft
rejection through direct, indirect and semi-direct presentation
[extensively reviewed by us in (61)]. Similarly, DCs have been
involved in the pathogenesis of many autoimmune diseases (62).
Animal studies have shown that Tregs can interact with DCs
in a leukocyte function-associated antigen-1 (LFA-1) dependent
manner (63) and down-regulate the expression of CD80/CD86
on target cells by CTLA-4 (Figure 1). However, in CTLA-4 KO-
mice Tregs could still suppress via compensatory mechanisms
involving TGF-β and IL-10 (64). Furthermore, Tregs have the
ability to increase the expression of Indoleamine 2,3-dioxygenase
(IDO) in DCs (Figure 1) (56). This enzyme catalyzes the
degradation of tryptophan to kyneurine leading to starvation of
effector cells. Unlike effector T cells, Tregs can express LAG3 a
homolog of the CD4 receptor. It binds to MHC-II with a
significantly higher affinity than CD4 mediating the activation
of PI3K/AKT, p42/44ERK, and p38MAPK pathways (65). As a
result, DCs exhibit an increased expression of co-stimulatory
molecules but reduced capacity to capture the antigens. In
addition to these cell-contact depended mechanisms, Tregs can
disrupt the microenvironment in the immunological synapse
provided by DCs and essential for T cells proliferation. In detail,
Tregs act either reducing the limiting enzyme for glutathione
(GSH) synthesis or consuming extracellular cysteine (66, 67).
Monocytes
Under inflammatory conditions, monocytes migrate into the
tissue, where they differentiate into dendritic cells or tissue-
resident macrophages. Monocytes constitute the major cellular
component in inflamed tissues and their regulation might
be key in reducing chronic inflammation. Tregs have been
demonstrated to directly act on monocytes inhibiting their
cytokine secretion, differentiation and antigen presenting
function. Following co-culture with Tregs, monocytes exhibited
classical features of M2 macrophages such as increased
expression of CD206 (mannose scavenger receptor) and CD163
(hemoglobin scavenger receptor), simultaneously these cells
showed a reduced capacity to respond to pro-inflammatory
stimuli as demonstrated by decreased production of IL-6 and
TNF-α and decreased NF-kB activation (68) (Figure 1). Recently
we have shown that ex vivo expanded Tregs are more efficient
in skewing monocytes toward a tolerogenic phenotype. Of note,
monocytes co-cultured with expanded Tregs showed a reduced
capacity to increase detrimental IL-17 producing T-cells when
compared to freshly isolated Tregs (69). This mechanism was
due to a decreased expression of CD86 by Tregs-conditioned
monocytes.
Granulocytes
Granulocytes are a group of cells belonging to the innate
immunity. Among them, neutrophils are the first to respond
to sites of inflammation where they phagocytose pathogens,
release proteolytic enzymes, and produce antimicrobial peptides.
Dysfunction of these cells results in sustained inflammation
which can cause a number of pathological conditions including
sepsis (70) and autoimmune diseases (71). Tregs directly
affect neutrophils (Figure 1) limiting their accumulation. They
do this by decreasing the expression of chemoattractants,
CXCL1 and CXCL2, thus preventing aberrant skin infiltration
Frontiers in Immunology | www.frontiersin.org 4 January 2019 | Volume 10 | Article 43
Romano et al. Tregs in Transplantation and Autoimmunity
FIGURE 1 | Treg suppressive mechanisms. Tregs are able to suppress different cell types by direct and indirect mechanisms. Tregs can produce anti-inflammatory
cytokines (IL-10, IL-35, and TGFβ) affecting T cells. In addition, they release perforin and granzyme, which damage target cell membrane leading to apoptosis. They
can sequester, by the high expression of CD25, IL-2 from the microenvironment reducing effector T cells proliferation. IL-2 starvation reduces NKs from proliferating
and exhibiting effector functions as well. Furthermore, NKs can be directly affected by Tregs in a membrane bound TGF-ß dependent manner. Tregs have been
observed to have a direct effect on B-cells via PDL1/PD-1 interaction and DCs via both CTLA-4 and LAG-3. CTLA-4 blocks co-stimulation reducing CD80/CD86
expression and it induces upregulation of IDO. The expression of CD39 on Tregs mediate the conversion to ATP to adenosine and AMP and reduce T effector
proliferation. Tregs can also skew monocyte toward M2 macrophages and prevent their differentiation in pro-inflammatory M1 macrophages. They can similarly induce
a suppressive phenotype in neutrophils and reduce ILC2 cytokine secretion.
(72). Furthermore, Tregs can also induce a more “immuno-
suppressive” phenotype in neutrophils, thus skewing the
microenvironment toward a less inflammatory one. Neutrophils
co-cultured with Tregs producedmore IL-10 and TGF-β together
with a decreased IL-6 production (73). In addition, Tregs induced
the expression of heme oxygenase-1, IDO and the suppressor of
cytokine signaling 3 molecule (SOCS3) (73).
Basophils are another subgroup of granulocytes which are
critical in mediating allergic and inflammatory responses. A
recent publication showed that Tregs were able to activate resting
basophils inducing their expression of CD69, CD203c, and CD13.
Further to these, activated basophils were able to release IL-4,
IL-8, and IL-13 (74).
Innate Lymphoid Cells (ILCs)
Recently described, ILCs are a subset of the innate immunity
arising from a lymphoid precursor. They are divided into three
groups depending on the expression of specific transcription
factors and cytokines [extensively reviewed in (75)] Natural Killer
cells (NKs) release cytokines, recruit other immune cells via
IFN-γ and TNF-α production and have direct cytotoxic activity.
Interactions between NKs and Tregs have been reported (76).
During pregnancy, Tregs suppress NKs to create a tolerant
environment favoring the implant (77) while in tumors Tregs
have the potential to block NKs generating an immune-
suppressive environment, which favors cancer cell survival (76).
Mechanisms of control exerted on NK cells by Tregs have been
investigated (Figure 1). Following activation, Tregs suppress NKs
via membrane bound TGF-β (78). This suppression results in the
inhibition of NK cells’ effector functions and a down regulation
of NKG2D receptors on cell surface. Further to this, by restricting
the availably of IL-2 in the microenvironment, Tregs prevent the
NKs from proliferating, secreting IFN-γ and enhancing missing
self-recognition (76). Tregs can also affect ILCs2. In particular,
iTregs but not tTregs have the ability to suppress ILC2 function
(Figure 1) preventing their secretion of both IL-5 and IL-13 in an
ICOS/ICOSL dependent-manner (79).
TREGS ISOLATION AND EXPANSION
Tregs can be isolated in large scale from either peripheral blood
(PB) (80), umbilical cord-blood (UCB) (81) or thymus (82). To
date, only Tregs isolated from UCB and PB have been tested in
the clinic. The isolation under GMP condition was carried out
by “CliniMACS” system (CliniMACS TM Instruments, Miltenyi
Biotec) a clinical-scale magnetic enrichment of cells in a closed
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and sterile system. The protocol consisted in either the depletion
of CD8+ and CD19+ cells or CD8+ only followed by an
enrichment of the CD25+ fraction. Although the CliniMACS
has been used by several groups for isolating Tregs, cell purity
represents an important limitation.. As reported byDi Ianni et al.,
only 80% of the cells were FOXP3+ due to the presence of cell
contaminants (83). The presence of non-FOXP3 cells might be
deleterious especially if the generation of antigen specific cells
has been planned. Another method used to isolate Tregs in the
clinic is the flow cytometry-based purification. Similar to the cell
sorter routinely used in the research field, cells can be isolated
according to the expression of selected cell markers. To date,
flow-sorted Tregs have been used in clinical trials outside the
EU (84, 85) where cells have been selected according to the
expression of CD4, CD25, and CD127 with high purity (>99%).
However, in the last few years, different companies have started to
develop GMP compatible cell sorter and fluorescent antibodies.
This will allow the isolation of CD4+CD25+CD127lowCD45RA+
Tregs, a subset more suitable for long-term expansion due to
an epigenetically stable FOXP3 expression and an increased
resistance to Th17 conversion (86). Moreover, this method does
not allow the isolation of activated effector cells that usually
express intermediated levels of CD25 and are increased in
autoimmune diseases. However, due to the high number of
processed PBMCs at the beginning, a pre-enrichment for CD4+
cells might be necessary. As a consequence, the cost for a single
preparation will increase considerably.
Another challenge for the research groups aiming to
start/develop new clinical trials with Tregs has been their low
number. In PB, Tregs are 5–10% of all the circulating CD4+ T
cells. Although in CB and thymus the number of Tregs is higher,
the infusion of a large cell number has been difficult to achieve.
The first clinical trial in GvHD used freshly isolated Tregs
(87). However, during the same period our group and others
developed a clinically scalable protocol for their expansions (88,
89). Tregs are now routinely expanded ex-vivo in 36 days using
anti-CD3/CD28-coated beads in the presence of high dose of IL-
2 (polyclonal expansion) (90). In detail, our protocol involves
the use of rapamycin, an immunosuppressant that inhibits
the mechanistic target of rapamycin (mTOR) protein kinase.
Rapamycin added during the course of the culture, inhibits
exclusively the proliferation of effector T-cells. In addition, by
blocking the signaling through AKT–mTOR-SMAD3, rapamycin
favors FOXP3 upregulation (91). Rapamycin confers to the
expanded Tregs higher stability and suppressive capacity; of
note, Tregs from TD1 patients and patients with cirrhosis on
a waiting list for a transplant expanded in the presence of
rapamycin recover their suppressive ability (80, 92). Together
with rapamycin and IL-2, Leventhal’s group has developed a
protocol to expand Tregs in the presence of TGF-β (93). At
the end of the expansion, their product was more suppressive
compared to the use of rapamycin alone and TSDR more
demethylated compared with the freshly isolated counterpart.
All-trans retinoic acid (ATRA) is another molecule that can
be used for Tregs expansion. Similarly to TGF-β, ATRA can
induce the generation of Tregs (94). During Treg expansion this
molecule is essential for the upregulation of chemokine receptors
responsible for gut homing like CCR9 and integrin-α4β7 (89).
Due to its peculiarity, ATRA will be used for the expansion
of Tregs in one of our clinical trials, “TRIBUTE” aiming to
evaluate the infusion of ex-vivo polyclonally expanded naïve
Tregs in patients with Crohn’s Disease. Umbilical cord blood-
derived Tregs have been isolated and expanded for the treatment
of GvHD (95). Cells were stimulated with anti-CD3 mAb and
artificial APC consisting of K562 cell lines (KT) engineered
to express CD86 and the high affinity Fc Receptor (CD64)
(KT64/86). During the 19 days culture, cells were supplemented
with 300 IU/mL of IL-2. Finally, the generation and expansion
of alloantigen specific Treg is a promising strategy that can
be tested soon in the EU with the advent of the GMP-cell
sorter. Our preclinical protocol for the generation and expansion
of antigen-specific Tregs involves the co-culture of Tregs with
CD40-activated allogeneic B-cells or donor-derived DCs in the
presence of IL-2. Antigen-specific Tregs have been shown to be
more powerful in suppressing alloimmune responses in vitro and
in vivo compared to the polyclonally expanded Tregs (96).
CLINICAL TRIALS ENROLLING
REGULATORY T CELLS
After 10 years from the first Treg infusion in patients with GvHD,
several phase I or phase I/II clinical trials have been completed or
started. They aim to test the safety, feasibility and efficacy of Treg
infusion in the setting of solid organ transplantation (97) GvHD
(98) and autoimmunity (84). In the next sections, we describe
results from published studies in the setting of autoimmune
diseases and transplantation giving an overview of the main
clinical trials that are ongoing.
Tregs in Autoimmunity
The first-in-man clinical trial adopting Tregs in autoimmune
diseases was the “CATS1” study, the results of which were
published in 2012 by Desreumaux et al. (99) In this phase
I/IIa, open-label, multicentric trial, 20 patients with active
and symptomatic refractory Crohn’s Disease were divided in
4 dose cohorts receiving a single infusion of 106-109 Tr1.
Firstly, PBMCs were cultured in the presence of ovalbumin
in medium supplemented with supernatant derived from
Drosophila Schneider 2 (S2). S2 cells were previously transfected
to produce IL-2 and IL-4 and express trans-membrane mouse
anti-human CD3, CD80, and CD58. After 7 days of culture
growing clones were harvested and tested for antigen specificity
and Tr1 cell identity before being expanded on Drosophila feeder
cells. Cell infusion has been considered safe and, the reported
unexpected severe adverse events were correlated to the natural
history of the disease rather than the treatment. In 2014 Marek-
Trzonkowska et al., published the results from a prospective,
non-randomized phase I trial with the purpose to evaluate safety
and feasibility of the infusion of autologous ex-vivo expanded
polyclonal Tregs in patients with recently diagnosed T1D (85).
Twelve patients aged 7–18 were enrolled and compared with
ten patients who met the eligibility criteria, whose blood could
not be collected due to inappropriate venous access. Fresh blood
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(250mL) was collected and Tregs (CD4+CD25+ CD127low) were
sorted and expanded using antiCD3/CD28 coated-beads, IL-2
and autologous serum without using rapamycin. Three patients
received a single dose of 10 × 106 cells/kg, other three patients
received 20 × 106 cells/kg, while six patients were offered a
double dose up to a total 30 × 106 cells/kg. The last group
was composed of those patients who showed good laboratory
and metabolic response, but symptoms of disease progression
after 6 months from the first infusion. After 1 year of follow-up,
safety was proved by the absence of serious adverse events and
eight patients showed signs of clinical remission, among those,
two remained insulin-independent. Conversely, the untreated
patients remained insulin-dependent with lower C-peptide levels.
In 2015, Bluestone et al. published results form an open-label,
interventional phase I clinical trial conducted at University of
California (San Francisco) and Yale University (84). They aimed
to determine safety and feasibility of intravenous infusion of
ex-vivo expanded autologous polyclonal Tregs in patients with
T1D. Fourteen recently diagnosed T1D patients, six females
and eight males, were divided into four dose cohorts, ranging
from 0.05 × 108 cells for cohort one to 26 × 108 cells for
cohort four, with 8-fold dose increase in each cohort. Two weeks
before the planned single infusion, 400ml of fresh peripheral
blood was collected; Tregs were isolated via Cell Sorting and
cultured for 14 days in the presence of antiCD3/CD28 coated-
beads and IL-2. Out of the sixteen eligible patients, two did not
receive treatment, due to failure in expanding Tregs. After a
mean follow-up of 31 months, only three severe adverse events
were reported (two hypoglycaemias, one ketoacidosis), while
no opportunistic infections were observed. None of the total
reported adverse events (mild to severe) was related to cell
infusion. Seven patients (cohort 3 and 4) received deuterium-
labeled Tregs in order to track the infused cells. After 1 day
post infusion, Tregs could be detected in circulation with a
peak observed by 7 to 14 days. The percentage of deuterium
labeled Tregs dropped to 25% after 3 months remaining stable
up to 9 months. After 1 year, deuterium was still detectable
in four patients with no evidence of differentiation of Tregs
into T effectors. Although this study showed a feasible and safe
therapeutic approach to T1D, with stably suppressive Tregs, the
small number of treated patients as well as the early phase of the
trial could not help to shed light on the optimal dose and the
impact of Tregs on the function of islet cells. To address these
points, a multicentre phase II randomized, placebo-controlled
double blind clinical trial (NCT02691247) is underway, with
the purpose to evaluate, in young patients, safety and effect
on beta cell function of a single dose (low 2.5 × 106/kg vs.
high 20 × 106/kg compared to placebo) of autologous ex-vivo
expanded polyclonal Tregs. Another ongoing phase I clinical
trial (NCT02772679) is evaluating safety and optimal dosing
of a single infusion of autologous ex-vivo expanded polyclonal
Tregs (CD4+CD25+CD127low) followed by injection of IL-2
in patients with T1D. The enrolled patients will be allocated
into two dose-cohorts receiving 3x106 cells/kg and 20 × 106
cells/kg, respectively. IL-2 (1 × 106 IU) will be administered
subcutaneously, daily, for the 5 consecutive days post infusion
and repeated after 1 month. The primary outcome will be
the occurrence of any adverse events and the evaluation of
distribution of deuterium-labeled Tregs.
In 2018, Dell’Era et al. published results from NCT02428309,
a phase I non-randomized, open-label study originally set to
evaluate escalating single dose of autologous, FACS-sorted and
ex-vivo polyclonally expanded Tregs (1 × 108, 4 × 108, and 16
× 108 cells, respectively) in adult patients with active cutaneous
Lupus (100). Due to screening failures and comorbidity burden,
a single patient was recruited, who received 1 × 108 deuterium-
labeled Tregs. The labeled cells in circulation were reduced after
4 weeks, while skin biopsies showed a marked increase in tissue
Tregs and IL-17 production by both CD4 and CD8 cells. Along
with the aforementioned, to date (end of November 2018) more
studies underway (Table 1). NCT03239470 is a phase I open-
label trial evaluating the infusion of a single dose (2.5× 108 vs. 10
× 108 cells) of sorted autologous polyclonally expanded Tregs in
adult patients with active cutaneous pemphigus. NCT03011021
is a phase I/II randomized open-label study, led by Central South
University Changsha, evaluating the infusion of 2 × 106/kg of
umbilical cord blood Tregs along with liraglutide therapy in
adult and elder patients with autoimmune diabetes. Patients
will be allocated in four groups: Tregs+liraglutide+insulin,
Tregs+insulin, liraglutide+insulin, insulin alone. The same
center is leading another randomized, open-label phase I/II
trial (NCT02932826) with the aim to compare, in T1D, the
infusion of umbilical cord blood Tregs combined to insulin
and insulin therapy alone. NCT02704338 is a phase I/II open-
label study on the infusion of a single dose of 10-20 x 106/kg
autologous ex-vivo polyclonally expanded Tregs in patients aged
10-70 with autoimmune hepatitis (Nanjing Medical University).
NCT03185000 (TRIBUTE) is a double-blind, placebo-controlled
trial (King’s College London), evaluating the infusion of sorted
and polyclonally expanded CD4+CD25+CD127lowCD45RA+
Tregs in adult patients diagnosed with moderate to severe
Crohn’s Disease not tolerating or responding to at least 2
standard treatments. Patients are divided in two groups, one
receiving Tregs at week 0 and placebo at week 8, the other
receiving placebo at week 0 and Tregs at week 8. Doses range
from 0.5–1× 106/kg, up to 8–10× 106/kg.
Tregs in Solid Organ Transplantation
Few reports regarding the infusion of Tregs in solid organ
transplantation have been published. In 2016, Todo et al.
treated 10 consecutive patients with end-stage liver failure who
underwent transplantation from a living donor with a cell
product enriched in anergic and/or regulatory T lymphocytes
(101). In detail, recipient lymphocytes and splenocytes (collected
during the transplant) were cultured with irradiated donor
cells in the presence of anti-CD80/CD86 antibodies for 2
weeks. Patients received a single infusion on day 13 post-
transplantation. Although the cell product was contaminated by
monocytes, DCs NK and B cells the numbers of Tregs infused
ranged from 0.43 × 106/kg to 6.37 × 106/kg. From the 40
patients originally planned, the trial ended due to the acute
cellular rejection during weaning in two patients with primary
biliary cirrhosis and one with primary sclerosing cholangitis.
Patients with no immunological related disease successfully
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TABLE 1 | Ongoing clinical trials adopting tregs in autoimmunity.
Study ID Phase Indication Enrollment/
Age
Product Dose Status
ISRCTN06128462 I Type 1 Diabetes 12/
range 5–18
Polyclonally expanded
tTregs (A)
10 and 30 × 106/kg Completed
NCT02691247 II Type 1 Diabetes 113/
range 8–17
Polyclonally expanded
tTregs (A)
2.5 and 20 × 106/kg Active, not recruiting
NCT02772679 I Type 1 Diabetes 16/
range 18–45
Polyclonally expanded
tTregs (A)
3 and 20 × 106/kg Recruiting
NCT02428309 I Cutaneous Lupus NA/
range 18–60
Polyclonally expanded
tTregs (A)
1, 4 and 16 × 108 Active, not recruiting
NCT03239470 I Pemphigus 12/
range 18–75
Polyclonally expanded
tTregs (A)
2.5 × 108 and 10 × 108 Recruiting
NCT03011021 I/II Type 1 Diabetes 40/
>18
Polyclonally expanded
tTregs (UCB)
2 × 106/kg Recruiting
NCT02932826 I/II Type 1 Diabetes 40/
range 6–60
Polyclonally expanded
tTregs (UCB)
2 × 106/kg Recruiting
NCT02704338 I/II Autoimmune hepatitis 30/
range 10–70
Polyclonally expanded
tTregs (A)
10–20 × 106/kg Unknown
NCT03185000 I/II Crohn’s Disease 20/
range 18–80
Polyclonally expanded
naive tTregs (A)
0.5–1, 3–5 and 8–10 × 106/kg Not yet recruiting
(A), autologous; (UCB), umbilical cord blood.
tolerated the immunosuppression weaning started after 6months
post-transplantation and followed by a complete weaning at 18
months. Patients with acute rejection underwent on low dose
of tacrolimus and mycophenolate mofetil. Although the infused
cell product was contaminated with antigen specific effector cells,
the authors presented this pilot study as a novel strategy for
tolerance induction in patients undergoing liver transplantation
for non-immunological diseases. To confirm this hypothesis,
investigations are currently underway in a large group of patients
excluding those ones with autoimmune disorders. In 2017,
results from phase I, open-label pilot study conducted at the
University of California (San Francisco) were published (102).
They aim to test the feasibility of Treg isolation, expansion and
infusion in kidney transplant recipients on immunosuppression
with subclinical graft inflammation. Three kidney transplant
recipients were enrolled according to their Kidney inflammation
status detected during the 6-month post-transplant surveillance
biopsy. Sorted Tregs (CD4+CD25+CD127low) were expanded as
described above using medium containing deuterated glucose
for further in vivo tracking. Patients received a single infusion
of around 320 × 106 and were maintained under tacrolimus,
mycophenolate mofetil and prednisone. Follow-up biopsies were
performed at 2 weeks and 6 months post-infusion. None of the
enrolled patients had infusion reactions and no infections or
malignancies were observed during the 1 year follow-up period.
The authors showed that infused Tregs peaked in circulation
the first week with deuterium signals detectable during the
first month after infusion in all subjects dropping near the
detection limit at 3 months after infusion. Due to the low
number of the enrolled patients, it is not possible to draw any
conclusion of either safety or efficacy of Treg infusion isolated
from kidney transplant recipients on immunosuppression with
subclinical graft inflammation. However, following the results
of this pilot study new trials have been planned to test this
strategy in a larger casuistic (NCT02088931 andNCT02711826).
In 2018, the results from the clinical trial conducted at the
Northwestern University (Chicago) called TRACT have been
published (93). This was a phase I dose escalation study infusing
ex vivo expanded autologous polyclonal Tregs into living donor
kidney recipients. Nine patients divided in 3 cohorts have been
infused 60 days post transplantation with 0.5, 1, and 5 ×
109 cells, respectively. Tregs were isolated from leukapheresis
collected 1 month prior to the transplant and expanded ex-vivo
for 21 days. Patients received alemtuzumab together with the
transplant for a complete lymphodepletion and 2 days before the
transplant, they were placed on tacrolimus and mycophenolate.
At 2 months post-transplant, prior to Treg infusion, tacrolimus
was stopped and switched to sirolimus. During the follow
up, no serious adverse events attributable to Treg infusion
were detected and the opportunistic infection seen were linked
with the immunosuppressive regimen. The authors found an
increased Treg number after the infusion compared to historical
control patients under the same immunosuppressive regimen.
The presence of donor specific antibodies was observed in
two patients but, the authors stated that this was due to the
suboptimal immunosuppression. Overall, the product was safe
and the authors are planning a phase II trial.
Most of the clinical trials using Tregs to prevent rejection
in solid organ transplantation are still ongoing (Table 2). We
are part of The ONe Study consortium where eight academic
institutions along Europe and US are testing safety and feasibility
of different regulatory cell populations (Tregs, tolerogenic DCs
and regulatory macrophages) in kidney transplant patients. The
ONe Study UK (NCT02129881) involved our institute (King’s
College London) and Oxford University; autologous Tregs
have been isolated from PB, magnetically enriched, polyclonally
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TABLE 2 | Ongoing clinical trials adopting Tregs in transplantation.
Study ID Phase Indication Enrollment/
Age
Product Dose Status
NCT02145325 I Living donor kidney
transplant
10/
range 18–65
Polyclonally expanded tTregs (A) 0,5, 1, 5 × 109 Active but not
recruiting
NCT02129881 I/II Living donor kidney
transplant
12/>18 Polyclonally expanded tTregs (A) 1, 3, 6 × 106/kg Completed
NCT02371434 I/II Living donor kidney
transplant
9/
range 18–65
Polyclonally expanded tTregs (A) 0,5, 1, 3 × 106/kg Unknown
NCT02244801 I/II Living donor kidney
transplant
16/
range 18–70
Donor-alloantigen-reactive tTregs (A) 300 and 900 × 106 Completed
NCT02091232 I/II Living donor kidney
transplant
8/>18 Belatacept-conditioned tTregs (A) 300 and 900 × 106 Active, not
recruiting
NCT02166177 I Liver transplant 9/
range 18–70
Polyclonally expanded tTregs (A) 0.5–1 and 3–4.5 × 106/kg Completed
NCT02188719 I Liver transplant 24/
range 21–70
Donor-alloantigen-Reactive Tregs (A) 50, 200, 800 × 106 Recruiting
NCT02088931 I Living donor kidney
transplant
3/
range 18–50
Polyclonally expanded tTregs (A) 320 × 106 Unknown
NCT02474199 I CNI reduction in liver
transplant
18/
range 18–70
Donor-alloantigen-Reactive Tregs (A) 400 × 106 Recruiting
NCT02711826 I Subclinical Inflammation in
Kidney Transplantation
40/>18 Donor-alloantigen-Reactive Tregs (A) 1 × 106/kg Recruiting
NCT01624077 I Liver transplant 1/
range 10–65
Induced Tregs (A) 1 × 106/kg Unknown
ISRCTN11038572 IIb Living donor kidney
transplant
136/>18 Polyclonally expanded tTregs (A) 5–10 × 106/kg Not yet recruiting
NCT01446484 I Kidney transplant (children) 30/
range 1–18
Polyclonally expanded tTregs (A) 200 × 106 Unknown
NCT03577431 I/II Liver transplant 9/
range 17–70
Belatacept-conditioned tTregs (A) from 2.5 to 500 × 106 Not yet recruiting
NCT03284242 NA Kidney transplant 12/
range 18–65
Polyclonally expanded tTregs (A) NA Not yet recruiting
(A), autologous; NA, not available.
expanded and then infused with no adverse effects in 12 patients.
Following the positive experience of this trial, a phase IIb trial
(The TWO study ISRCTN11038572) will start at the end of 2018.
In this new study, 34 renal transplant recipients will be enrolled
and infused with expanded Tregs 6 months after transplantation.
The primary outcome will be the incidence of acute rejection
episodes at 12 months post-transplantation. The ONe Study-
Charité in Berlin (NCT02371434) is also evaluating polyclonally
expanded Tregs while, the group in Milan is testing the effects
of Antigen-specific Tr1 (T10 cells). Tregs specific for the donor
alloantigens (DarTregs) have been tested by the US-partner of
the ONe study (University of California, NCT02244801 and
Massachusetts General Hospital, NCT02091232). In California,
sorted Tregs have been co-cultured firstly with donor B
cells activated using CD40L and then re-stimulated using
antiCD3/CD28 coated-beads (96). In Boston, PBMCs were
co-cultured for 72hrs with an equal number of irradiated
kidney donor PBMCs (first-party stimulators) in the presence
of belatacept (CTLA4 blocking Ig) and then re-stimulated with
new first-party stimulator without co-stimulatory blockage (103).
In both trials, patients have been divided in 2 cohorts receiving
300 × 106 and 900 × 106 of darTregs respectively 10 days
after the transplant. The Russian State Medical University in
Moscow is leading a phase I clinical trials where two doses
of Tregs will be infused in pediatric patients after kidney
transplantation (NCT01446484). Patients will be treated at
day−21,−14 and the day of the transplant with alemtuzumab
(monoclonal antibody specific for CD52). On day 0, patients
will receive either tacrolimus or cyclosporine followed by
mycophenolate mofetil at day 3. Sirolimus will start 1 month
after the transplant together with the first infusion of Tregs.
The second dose will be administrated after 3 months post-
transplant. Although this clinical trial was supposed to end
in 2014, no results are available. Other two clinical studies in
the US (NCT03284242 and NCT02145325) are testing safety
and feasibility of Tregs after kidney transplantation. The ThRIL
(NCT02166177) is a Phase I/IIa clinical trial conducted at
King’s College London. We aimed to test polyclonally expanded
Tregs in liver transplant patients. The last patient was infused
in 2017 and early data are already available. Two different
multicentric studies running at the University of California
(San Francisco), Northwestern University, (Chicago), and Mayo
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Clinic (Rochester) are testing DarTregs in liver transplant
recipient. The first one (NCT02474199) aims to test safety
and feasibility of DarTregs infusion only, while in the second
(NCT02188719) they aim to infuse Tregs and reducing the use
of calcineurin inhibitors. In NCT02474199, patients will receive
a target dose of 400 × 106 darTregs infused intravenously while
in NCT02188719 four cohorts of patients will receive none,
50 × 106, 200 × 106, 800 × 106 darTregs, respectively. Both
studies are still recruiting and results will not be available soon.
In August 2018, at the Massachusetts General Hospital a new
single-center, open-label, non-randomized clinical trial started
(NCT03577431). In this phase I/II study they aim to use Tregs
to facilitate immunosuppression withdrawal in liver transplant
recipients. Similarly to what has been used for the kidney
recipients in the ONe study, a cell product containing donor-
specific hyporesponsive cells in associationwith allospecific Tregs
will be used. This cell product is generated in mixed leukocyte
reaction where donor and recipient cells are co-cultured in the
presence of belatacept. They have planned the infusion of 2.5 ×
106 up to 500× 106 cells in nine patients.
FUTURE DIRECTIONS
Although preclinical studies have shown the capacity of Tregs
to treat autoimmune diseases and prevent graft rejection, in
the clinic we are still far away from these ultimate goals. The
first clinical studies have shown the safety and feasibility of
Tregs infusion and new phase II trials are now starting or being
planned. The next steps will be crucial to define a standardized
strategy for treating autoimmune disease and graft rejection.
One important aspect is represented by the immunosuppressive
regimen used to dampen the immune response. We have
recently shown that immunosuppressive drugs like tacrolimus,
mycophenolate and methylprednisolone reduced Tregs’ viability
and proliferation in a dose dependent manner (104). Therefore,
the immunosuppressive regimen adoptedmight have an essential
role for the efficacy of the Tregs therapy. This is the reason
why different strategies are now under investigation with the
aim to tailor the immunosuppressive regimen to the Tregs or
find the best timing for their infusion. As described in the
previous section, the infusion of Tregs can be executed when
patients are under rapamycin treatment. Differently to the other
immunosuppressive drugs, rapamycin favors the expansion of
Tregs both in vivo (105) and in vitro (90, 92) supporting their
action. We believe that Tregs need to be injected in combination
with other therapies tailored to the type of disease that is to
be targeted. In other words, combined therapy protocols might
represent a winning strategy for the future. To date, low doses of
IL-2 have been used for expanding endogenous circulating Tregs
in autoimmunity (106) and GvHD (107) directly in vivo. The
main issues of this approach are represented by both the half-
life of the IL-2 in circulation together with the possible activation
of other detrimental cells like NK or eosinophils. New clinical
trials (NCT03556007, NCT03221179, and NCT03451422) are
testing molecularly engineered IL-2 with an increased half-
life. This will allow the minimization of the dose of IL-2
administrated and the development of a more specific therapy
for Tregs. Another promising strategy of combined therapy in
autoimmunity is represented by the engagement of the TNF
receptor 2 (TNFR2). TNF-blocking strategies are effective for
the treatment of rheumatoid arthritis (22, 108) however the
inflammatory effect of the TNF-alpha is mediated by the receptor
1 (TNFR1) while the TNFR2 has been shown to induce immune
modulation and tissue regeneration. Tregs express higher levels
of TNFR2 compared to other T cells and its expression has
been linked with Treg suppressive ability in both mice (109)
and human (110, 111). Due to the role of this receptor, TNFR2
antagonism has been suggested as a new promising strategy
in cancer immunotherapy specifically in ovarian, lung, and
cutaneous T cell lymphoma (112, 113). In addition, a defective
TNF/TNFR2 interaction is critical for Treg functionality in
autoimmunity. For this reason, the combined infusion of antigen
specific Tregs together with TNFR2 agonists might be a winning
strategy. In the last years, several reports have shown how
chronic inflammation changed the microbiome composition
which is essential for developing regulatory pathways involved
in the maintenance of the immune homeostasis (114). To further
reduce the systemic inflammation, the infusion of Tregs can be
applied in combination with Treg-inducing microbial as fecal
microbiome transplantation is not yet approved in clinic due to
safety reasons. Recent studies have highlighted the importance
of short chain fatty acids derived from bacteria as main factors
mediating Treg induction. Butyrate has been implied in the
up regulation of anti-inflammatory genes in DCs. Furthermore,
it enhances histone acetylation of the Foxp3 locus and the
stability of FOXP3 protein (115). Finally, polysaccharide A
and cell surface β-glucan/galactan from Bifidobacterium bifidum
were able to induce Foxp3+IL-10highIFN-γlow and Foxp3−IL-
10highIFN-γhigh Tregs, respectively (116). For this reason, Treg-
inducing microbial components can ameliorate the outcome of
cell therapy protocol adopting Tregs.
Treg localization and migration represent the main challenges
in the field. Cells delivered specifically to inflamed area will
increase enormously the positive outcome of the cell therapy
protocol based on Tregs. As already discussed above in this
review, the use of ATRA during Tregs expansion has been
shown to induce chemokine receptor specific for gut homing The
discovery of the Th-like Tregs has opened another important
avenue in selecting a population tailored to the type of disease.
In autoimmunity, therapies targeting Th17-dependent pathways
are associated with clinical benefits (117); in this scenario, Th17-
like Tregs might be the ideal candidates for cell therapy protocols.
Cardiac allograft vasculopathy after heart transplantation is
linked to Th-1 and the use of Th1-like Tregs might be the
ideal strategy. However, due to the low number of the Th-like
Treg subpopulation, ex-vivo expansion is necessary. This might
modify their phenotype especially if rapamycin or other drugs are
added into the culture. Overall, new studies on these cells need
to be conducted before including them as possible candidate for
cell therapy. An important aspect that needs to be considered in
developing Phase II/III trials will be the tracking of the infused
cells. To date, only Tregs infused in patients with T1D have
been monitored using deuterium labeling (84). However, this
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strategy is limited to the circulating cells and it is not possible
so far to gain information on the localization of Tregs in the
tissues. For this reason, future trials need to test new approaches
for a more specific cell detection. One possibility is represented
by the sodium-iodide symporter (NIS) a molecule expressed on
thyroid follicular cells and essential for the uptake of plasma
iodide (118). The NIS gene was firstly cloned in 1996 by Dai
et al. (119) and it is considered safe, non-immunogenic and non-
invasive. Although it mediates mainly the transport of iodide into
the cells, NIS can translocate several other substrates detected
using different system like PET or SPECT/CT. Transducing Tregs
with NIS will be key for understanding their localization and
whether they successfully reach the target organ or tissue. In
addition, compared to the iron oxide nano-particles that persist
after death of the labeled cell, NIS works only on living cells
allowing at the same time the evaluation of cells viability in vivo.
We have already developed a protocol for transducing Tregs with
NIS (120). NIS expressing self-specific Tregs were radiolabelled
in vitro with Technetium-99m pertechnetate with no effects on
cell viability, phenotype, and function. Moreover, we were able
to detect these cells in vivo in the spleen of C57BL/6 mice 24 h
after infusion by SPECT/CT. Lastly, enthusiasm is growing in
the generation of antigen-specific Tregs by genetic engineering
with chimeric antigen receptors (CARs). This new strategy
[extensively reviewed in (121)] has been firstly developed in the
tumor field and in 2017, the FDA approved the use of CAR T-cell
for the treatment of acute lymphoblastic leukemia in children and
advanced lymphomas in adults (122). In autoimmune diseases,
CAR-T cells might be developed for targeting the pathological
cells responsible of the autoimmune reaction (B cells). On the
other hand, CAR can be transduced into Tregs to generate a
population that is specific for a selected antigen. Due to the
lack of self-protein exclusively expressed on the inflamed tissue,
the generation of CAR specific Tregs in autoimmune diseases
is challenging (123). Conversely, in transplantation, CAR-Tregs
specific for MHC-I molecules have been generated. In the
context of HLA-mismatched transplant, HLA class I specific-
CAR-Tregs will target the transplanted organ without interfering
with the recipient-immune system. We have shown how HLA-
A2 (MHC class I protein) specific CAR Treg have the capacity
to prevent skin-graft rejection in a mouse model compared with
polyclonally expanded Tregs (124). However, before being tested
in the clinic, CAR-Treg stability is another issue to be solved
together with cell homing capacity. In fact, as CAR-Tregs are
antigen specific, they do not need to migrate into the lymph node
but can be specifically directed into the target organ/tissue.
CONCLUSIONS
So far, many of the original questions for the use of Tregs in
transplantation and autoimmunity remain unanswered. Results
from the ongoing clinical trials will be crucial to better
understand the tolerated Treg dose, timing of infusion and the
immunosuppressive regimen to preserve/favor them. However,
few data will be available on Tregs efficacy and whether or not
we should engineer them for being antigen-specific or expressing
molecules linked with the migration into the target tissue/organ.
A big step forward to understand the real potential of Treg-based
cell therapy will be there in vivo tracking. However, due to the
high costs of cellular engineering and ethical approval this will
not be revealed soon. For this reason, in the near future, the
best strategy is represented by the combined therapy whereby
antigen-specific Treg will be infused together with either low dose
of IL2, rapamycin or in the future TNFR2 agonists.
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